Showing 2151-2160 of 5771 results for "".
- Second Sight Announces Departure of Will McGuire, President and CEO, and Appointment of Gregg Williams as Acting CEOhttps://modernod.com/news/second-sight-announces-departure-of-will-mcguire-president-and-ceo-and-appointment-of-gregg-williams-as-acting-ceo/2477384/Second Sight Medical Products announced the departure of Will McGuire, President and Chief Executive Officer, effective March 27, 2020, to pursue another professional opportunity located closer to his family. Mr. McGuire remains as a director on Second Sight’s board. Effective March 27, 20
- ARVO Annual Meeting Cancelledhttps://modernod.com/news/arvo-annual-meeting-cancelled/2477380/Due to the COVID-19 outbreak, the Board of Trustees at The Association for Research in Vision and Ophthalmology (ARVO) has decided to cancel its annual meeting, scheduled to take place May 1–7 in Baltimore. The ARVO organizers released an emailed statement to its membership outlining the d
- ImprimisRx Announces Supply Agreement with EyeCare Services Partnershttps://modernod.com/news/imprimisrx-announces-supply-agreement-with-eyecare-services-partners/2477379/ImprimisRx announced that it has agreed to a product supply agreement with EyeCare Services Partners (ESP). ImprimisRx currently provides a limited number of ophthalmic formulations to practices within the ESP group, but this agreement will expand the number of formulations availa
- Alcon Announces European Launch of Vivity Presbyopia-Correcting IOL With X-WAVE Technologyhttps://modernod.com/news/alcon-announces-european-launch-of-vivity-presbyopia-correcting-iol-with-x-wave-technology/2477377/Alcon announced that the AcrySof IQ Vivity IOL is now commercially available in select European markets, with additional countries to follow throughout 2020. The latest innovation in Alcon’s portfolio of presbyopia-correcting IOLs (PC-IOLs), Vivity is the first-of-its-kind, extended range
- Aldeyra Announces Strategic Prioritization of Late-Stage Clinical Pipeline in Ocular Diseasehttps://modernod.com/news/aldeyra-announces-strategic-prioritization-of-late-stage-clinical-pipeline-in-ocular-disease/2477378/Aldeyra Therapeutics announced strategic prioritization of late-stage ocular disease programs in allergic conjunctivitis, dry eye disease, and proliferative vitreoretinopathy. In conjunction with the strategic prioritization, Aldeyra appointed ophthalmology drug development expert James A. Gow, M
- AAD Annual Meeting Becomes Latest Casualty of COVID-19 Outbreakhttps://modernod.com/news/aad-annual-meeting-becomes-latest-casualty-of-covid-19-outbreak/2477371/The American Academy of Dermatology (AAD) annual meeting became the latest casualty of the COVID-19 outbreak, with the conference cancelled on Tuesday. The meeting was scheduled to be held from March 20 to 24
- Registration Now Open for Neuro-Optometric Rehabilitation Association (NORA) 2020 Annual Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-nora-2020-annual-conference/2477365/Registration is now open for the Neuro-Optometric Rehabilitation Association, International (NORA) Clinical Skills Pre-Conference (September 10-11) and 29th annual General Conference (September 12-13) at the Hyatt Regency Columbus in Columbus, Ohio. “This year’s conference them
- Sight Sciences Announces Publication of First-Ever Multicenter MIGS study in Childhood Glaucomahttps://modernod.com/news/sight-sciences-announces-publication-of-first-ever-multicenter-migs-study-in-childhood-glaucoma/2477366/Sight Sciences announced that positive outcomes from a new multicenter study of one of the OMNI Surgical System’s predecessor devices, TRAB360, were published in the
- ImprimisRx Announces Supply Agreement with iOR Partnershttps://modernod.com/news/imprimisrx-announces-supply-agreement-with-ior-partners/2477364/ImprimisRx announced that it has agreed to a product supply agreement with iOR Partners. Under the agreement, ImprimisRx will provide a variety of formulations needed for in-office surgeries, including the MKO Melt and various injectable and topical products.
- Kala Pharmaceuticals Announces Statistically Significant Results in STRIDE 3 Trial of Dry Eye Disease Drug Eysuvishttps://modernod.com/news/kala-pharmaceuticals-announces-statistically-significant-results-in-stride-3-trial-of-dry-eye-disease-drug-eysuvis/2477360/Kala Pharmaceuticals announced positive topline results from STRIDE 3, a phase 3 clinical trial evaluating KPI-121 0.25%, which Kala plans to commercialize under the brand name Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25%, for the treatment of dry eye disease. STRIDE 3 met b